On behalf of Magellan Rx Management, here is the quarterly communication document outlining the drug changes for the upcoming quarter beginning July 1.
Product Update Background:
The Pharmacy and Therapeutics Committee (P&T), Therapeutic Assessment Committee (TAC), and Value Assessment Committee (VAC) meet periodically to review the status of each formulary and make recommendations. As a result of these periodic reviews, the Formulary may be modified. This update summarizes formulary and utilization management (edit) changes resulting from the committees’ most recent meetings.
Product Update Communications Plan:
If applicable, members with a prescription for any drug moving to Tier 3 status will receive a personalized letter naming the drug and identifying formulary therapeutic alternatives (Tier 1 & Tier 2) within two months of the effective date of this change.
Talking Points:
The Pharmacy and Therapeutics (P&T), Therapeutic Assessment Committee (TAC), and Value Assessment Committee (VAC) make changes to the formulary to help ensure that plan members have access to quality, safe and cost-effective prescription benefits.
If you have any questions regarding these changes, please feel free to contact your Account Manager or Sales Representative.
